Gilead’s Trodelvy cleared a key EU hurdle, but can it really replace chemotherapy in first-line TNBC?
CHMP backs Trodelvy plus Keytruda for first-line PD-L1-positive metastatic TNBC, moving Gilead closer to an expanded EU label.
Pharma & Biotech
Pharma & Biotech
Arcus Biosciences’ August 5 call looks routine, but its biggest pipeline test is approaching
Arcus Biosciences will report Q2 results on August 5 as investors assess casdatifan progress, pipeline execution and its cash runway.
Pharma & Biotech
Can one HIV pill a week replace daily therapy? Gilead and Merck’s Phase 3 data raise the stakes
Gilead and Merck’s weekly HIV pill preserved suppression in two Phase 3 trials, strengthening the case for regulatory filings.
Pharma & Biotech
Merck and Gilead secure FDA approval for a new ADC-immunotherapy backbone in advanced TNBC
The new regimen replaces conventional chemotherapy with a Trop-2-directed antibody-drug conjugate while retaining PD-1 blockade, offering longer disease control but leaving overall survival, sequencing and cost questions unresolved.
Pharma & Biotech
Gilead expands Trodelvy into first-line metastatic TNBC, but survival questions remain unresolved
The decision gives clinicians a Trodelvy-based option for patients who cannot receive checkpoint inhibitors and a Trodelvy plus Keytruda regimen for PD-L1-positive disease. The immediate clinical impact is substantial, although immature overall-survival data, toxicity management and treatment cost will influence how rapidly the new pathways displace chemotherapy.
Pharma & Biotech
Gilead’s once weekly Yeztugo bid could challenge the old daily pill versus injection divide
Read how Gilead’s once weekly oral Yeztugo filing could reshape HIV prevention, PrEP adherence and long acting therapy competition.
Pharma & Biotech
Gilead and Merck pipeline update reveals promise in HIV and pressure in oncology
Gilead and Merck gain HIV momentum but face fresh oncology questions. See why this split pipeline update matters.
Pharma & Biotech
Why Gilead Sciences’ Livdelzi data could reshape treatment goals in primary biliary cholangitis
Find out how Gilead Sciences’ Livdelzi trial data could reshape PBC treatment goals and strengthen the case for ALP normalization.
Pharma & Biotech
Why Gilead’s visceral leishmaniasis collaboration with WHO matters beyond drug donation
Gilead’s WHO pact targets kala-azar access, but diagnostics, treatment delivery and East Africa execution will decide the impact.
Pharma & Biotech
Why Gilead’s $5bn Tubulis deal could reshape its solid tumour pipeline strategy
Gilead’s Tubulis deal strengthens its ADC pipeline, but oncology execution, safety and clinical proof now decide the upside.